The Russian Direct Investment Fund (RDIF) signed an agreement with the leading Turkish pharmaceutical company of anti-COVID-19 Sputnik V vaccine production in and started technology transferring, RIA Novosti reported with reference to the fund.
“The potential volume production is million doses of the Sputnik V vaccine per year, and the possible production expansion in the future is also being discussed. The vaccine delivery of the will be carried out both to the domestic market within Turkey and to other countries”, the fund also noted.
Turkish partners show great interest to the vaccine, the effectiveness of which is over 90%. The Sputnik V vaccine is based on the human adenovirus vector platform and has already received regulatory approval in Russia, Belarus, Argentina, the UAE, Hungary, Serbia, Bolivia, Algeria, Palestine, Venezuela, Paraguay and Turkmenistan.
